Pdx1 and Ngn3 Overexpression Enhances Pancreatic Differentiation of Mouse ES Cell-Derived Endoderm Population

Atsushi Kubo1*, Robert Stull2, Mitsuaki Takeuchi1, Kristina Bonham2, Valerie Gouon-Evans3, Masayuki Sho4, Masayuki Iwano1, Yoshihiko Saito1, Gordon Keller5, Ralph Snodgrass2

1 First Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan, 2 VistaGen Therapeutics, Inc., South San Francisco, California, United States of America, 3 The Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York, United States of America, 4 First Department of Surgery, Nara Medical University, Kashihara, Nara, Japan, 5 McEwen Centre for Regenerative Medicine, Toronto, Canada

Abstract

In order to define the molecular mechanisms regulating the specification and differentiation of pancreatic β-islet cells, we investigated the effect of upregulating Pdx1 and Ngn3 during the differentiation of the β-islet-like cells from murine embryonic stem (ES) cell-derived activin induced-endoderm. Induced overexpression of Pdx1 resulted in a significant upregulation of insulin (Ins1 and Ins2), and other pancreas-related genes. To enhance the developmental progression from the pancreatic bud to the formation of the endocrine lineages, we induced the overexpression of Ngn3 together with Pdx1. This combination dramatically increased the level and timing of maximal Ins1 mRNA expression to approximately 100% of that found in the βTC6 insulinoma cell line. Insulin protein and C-peptide expression was confirmed by immunohistochemistry staining. These inductive effects were restricted to c-kit+ endoderm enriched EB-derived populations suggesting that Pdx1/Ngn3 functions after the specification of pancreatic endoderm. Although insulin secretion was stimulated by various insulin secretagogues, these cells had only limited glucose response. Microarray analysis was used to evaluate the expression of a broad spectrum of pancreatic endocrine cell-related genes as well as genes associated with glucose responses. Taken together, these findings demonstrate the utility of manipulating Pdx1 and Ngn3 expression in a stage-specific manner as an important new strategy for the efficient generation of functionally immature insulin-producing β-islet cells from ES cells.

Introduction

Islet transplantation has been shown to be useful in the treatment of patients with type 1 diabetes, even resulting in insulin independence [1,2]. However, this therapeutic approach is limited by a shortage of transplantable islets. Consequently, other potential sources of β-islet cells are currently being sought. Two such alternatives are pancreatic duct cells and endocrine progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-producing cells are pluripotent stem cells (ES or iPS), which are progenitor cells [3–5]. Another possible source of insulin-produc
of endocrine progenitors into insulin producing β-islet cells. These factors must be expressed in a correct temporal order for appropriate lineage specification and differentiation of gut endoderm, pancreatic progenitors, endocrine progenitors and, finally, pancreatic β-islet cells.

We previously established a protocol for the activin-induced development of definitive endoderm during mouse ES cell differentiation [21,22]. Similarly, D’Amour et al. reported that pancreatic hormone-expressing endoderm cells can be differentiated from human ES cell-derived endoderm through induction with activin [23,24]. They further showed that the soluble growth factors that participate in pancreatic development during human embryonic development can mimic that process during human ES cell differentiation in vitro [23,24].

In the present study, we evaluated the transcriptional regulation that is critical for induction of β-islet cell differentiation from mouse ES cell-derived endoderm. Previous studies have demonstrated that biphasic induction of Pdx1 induces insulin producing cells in ES cell derived endoderm [25]. In this study, we show that temporally controlled expression of Pdx1 and Ngn3 induces pancreatic endocrine genes, various β-islet cell-related transcription factors, including Pax4, Pax6, Is11 and Nkx2.2, and efficiently yields a high frequency of β-islet cells that express very high levels of insulin. Lastly, although these β-islet cells appropriately process and secrete insulin and C-peptide protein in response to various insulin secretagogues, they do not demonstrate adult levels of glucose-controlled insulin secretion.

**Results**

**Pdx1 induces insulin mRNA expression in activin-induced endoderm embryoid bodies (EBs)**

It is well known that Pdx1 is a master gene for early pancreatic development from the gut tube, and previous protocols resulted in very modest levels of Pdx1. Therefore, we engineered ES cells with a doxycycline (Dox)-inducible Pdx1 ("tet-pdx1 ES cells") expression vector to evaluate the effect of temporal control of Pdx1 upregulation. For these studies we used Protocol #1 ("SP protocol") as previously described [21]. Pdx1 expression was induced in the cells by adding Dox (1 μg/ml) to the EB cultures between days 6 and 20. Dox-induced Pdx1 expression was confirmed by reverse transcription-polymerase chain reaction (RT-PCR) performed on days 6, 10, 14, 17 and 20 of differentiation (Fig. 1A). Overexpression of Pdx1 protein resulted in an upregulation of Ins1 and Ins2 mRNA expression seen as early as day 10 for Ins1 and day 14 for Ins2, and they reached maximum levels at day 17 (Fig. 1A). Ins1 is express only in pancreas, whereas Ins2 is expressed in both pancreas and brain [26,27]. Quantitative PCR analysis revealed that the normalized (see Methods) level of Ins1 expression at day d20 represents 0.08% of the expression seen in the βTC6 insulinoma cell line [ATCC CRL-11306] (Fig. 1B). For comparison, normalized Ins1 mRNA levels in mouse pancreatic islets are approximately 140% of the βTC6 levels (data not shown).

**Co-expression of Ngn3 with Pdx-1 increases insulin mRNA expression in activin-induced endoderm EBs**

Because levels of Ins1 mRNA are much lower in the ES differentiated cells than in βTC6 cells, and the fact that Ngn3 levels in these cultures is very low (data not shown), we next evaluated the effects of Ngn3 and other factors to improve β-islet cell differentiation and insulin expression. To do this, we transiently expressed target genes by cloning them into pIRES2-EGFP and electroporating the vectors into cells isolated from day 6 EBs under Protocol #1. Subsequent FACS analysis confirmed that this method produced about 42% GFP-positive cells 2 days after electroporation (Fig. 1C). Using this system, we transiently overexpressed Ins1, Nkx6.1 and Ngn3, all of which are known to be important for β-islet cell specification, in cells with Dox-induced Pdx1 expression. RT-PCR or real time PCR on day 9 showed that all genes were expressed 3 days after electroporation and that only Ngn3 induced Ins1 expression at significant levels (Fig. 1D). The transient upregulation of Ngn3 resulted in a significant increase above Pdx1 alone in the normalized expression of Ins1 to approximately 0.07% of the βTC6 level, which was dependent on the Dox-induced upregulation of Pdx1 (data not shown). It is important to note that this transient Ngn3 expression, together with Pdx1, dramatically accelerated Ins1 mRNA expression, and significantly higher levels of Ins1 (data not shown).

To further characterize this effect, we generated Ainv cells capable of stable Dox-induced co-expression of Pdx1 and Ngn3 using a bi-cistronic Pdx1-IRES-Ngn3 inducible expression construct. When Dox was added on day 6, normalized levels of Ins1 mRNA increased to a maximum level by day 9, which was approximately 1.5% of the levels seen in βTC6 (Fig. 1E). Similarly, Gcg expression appeared on day 9 after upregulating both Pdx1 and Ngn3 (Fig. 1F). These data are consistent with the transient expression data presented in Figure 1D and suggest that stable co-expression of Ngn3 and Pdx1 increases Ins1 mRNA levels about 20-fold higher than overexpression Pdx1 alone, shortens the time to peak Ins1 mRNA levels from 20 days to 9 days (compare Fig. 1B with 1E), and results in the differentiation of β-cell production of glucagon.

**Suspension culture in the presence of BMP4 enhances Ins1 gene expression induced by Pdx1 and Ngn3**

Recently, Gouon-Evans et al. showed that BMP4 is required for hepatic differentiation of mouse ES cell-derived definitive endoderm [22]. The recent work of Wandzioch and Zaret also actually shows that in the mouse embryo, BMP is required at a later time point for pancreas specification compared to liver specification [28]. They show that an early activation with BMP4 would block pdx1 expression from endoderm (but induces alb expression), while is necessary few hours later to induce pdx1. These results suggested a dynamic role of BMP4 to induce liver and pancreatic differentiation [28]. In this study, we evaluated the effect of BMP4 on the differentiation of insulin producing cells from mouse ES cell-derived definitive endoderm. After two passages on gelatin, dissociated tet-pdx1/ngn3 ES cells were cultured for 2 days as EBs using Protocol #2 in serum-free differentiation medium, as previously described ("SFD protocol") [22]. Activin A was then added from day 2 to day 4 to induce definitive endoderm, and on day 4, the effects of Dox and BMP4 were evaluated. Without Dox, no Ins1 mRNA was detected on day 6 or 9 (data not shown). When Dox was added on day 4 to induce Pdx1 and Ngn3 expression, normalized Ins1 mRNA levels reached 0.6% on day 6 and 3.1% on day 9 of differentiation of βTC6 levels (Fig. 2A). It was noticed that some of the day 6 EBs which were replated on gelatin coated well plates attached on the plate and formed a monolayer, while others remained in suspension. The floating EBs were transferred to a low-cluster dish (12-24 well plate, Corning) on day 7. On day 9, all cells remained floating in these cultures and the Ins1 mRNA levels were significantly higher in these cells than in the monolayer cells cultured on the gelatin coated dishes, reaching 4.9% of βTC6 levels (Fig. 2B). In a subsequent experiment, Dox was present continuously from day 4 and EBs were cultured with BMP4, bFGF and activin A from day 4 to day 6 and then transferred to low-cluster dishes (12- or 24-well) until day 16. Under these conditions expression of Ins1 and Ins2 mRNA continued to increase until day 16, reaching 13.2% and 8.2% of
TC6 levels, respectively (Fig. 2C). Thus supplementing the Protocol #2 with BMP4 and culturing in suspension increased Ins1 mRNA levels about 10-fold, as compared to the Protocol #1.

Insulin-expressing pancreatic cells are derived from a CXCR4/c-kit+ population

We previously showed that cells positive for both CXCR4 and c-kit give rise to definitive endoderm and hepatocytes [22]. Here we tested whether this same population also gives rise to pancreatic cells. EBs were cultured using Protocol #2 for 4 days, after which they were trypsinized to obtain suspensions of single cells, and immunostaining was then used to detect CXCR4 and c-kit. The stained cells were sorted and the CXCR4 and c-kit double positive and double negative populations were reaggregated for 2 days using Protocol #2. When reaggregated EBs were replated on gelatin-coated dishes on day 6 using Protocol #2, most double positive CXCR4/c-kit+ cells attached to the dishes, whereas most double positive CXCR4/c-kit+ endodermal cells did not attach but remained in suspension as EBs. On day 9, no Ins1 mRNA was detected in the adherent monolayer of CXCR4/c-kit(−) cells.
whereas levels of \textit{Ins1} mRNA in EBs from CXCR4/c-kit\(^{+/+}\) cells were more than 2-fold higher than in pre-sorted EBs (Fig. 2D). This suggests that, like ES-derived hepatocyte-like cells, ES-derived pancreas-like cells are derived from a CXCR4/c-kit\(^{+/+}\) definitive endoderm population, which differentiates more efficiently in a 3-dimensional non-adherent structure as opposed to a 2D monolayer. Interestingly, these isolated endodermal cells produced small EBs that did not grow well. We could not continue to culture the 3-dimensional non-adherent structures beyond day 9. They did not grow well and tended to disrupt. We suspect that there may be a requirement for a non-endodermal cell for maintenance and growth of the pancreas cells under these conditions.

Pancreas-related genes induced by Pdx1 and Ngn3 under Protocol \#2 with BMP4

RT-PCR was used to evaluate the expression of \textit{Ins1} and a variety of pancreas-related genes from cells cultured in suspension with BMP4 under Protocol \#2. These studies revealed that overexpression of Pdx1 and Ngn3 induced the following genes: 1) secretory pancreatic endocrine genes (\textit{Ins1}, \textit{Ins2}, \textit{Gcg}, \textit{Sst}, \textit{Ppy} and \textit{Ghrl}), incretin hormone related-genes (\textit{Gip} and \textit{Glp1r}), and exocrine genes (\textit{Amy} and \textit{Ela}) (Fig. 3A); 2) genes related to insulin secretion and insulin processing (\textit{Pcsk1}, \textit{Pcsk2} and \textit{Chga}), genes related to glucose sensing (\textit{Glut2} and \textit{Gck}), and genes related to potassium ion channels (\textit{Kir6.2}) (Fig. 3B); and 3) pancreas-related transcription factor genes (\textit{Ptfa1}, \textit{Pax4}, \textit{Pax6}, \textit{NeuroD}, \textit{Is1}, \textit{Nkx2.2}, \textit{MafA} and \textit{Hex}) (Fig. 3C). It is interesting to note that the liver- and intestine-related genes \textit{Alb}, \textit{Afp} and \textit{Fabp2} were suppressed by Dox induction, as was \textit{Shh}, an inhibitor of pancreatic endoderm (Fig. 3A).

Microarray analysis of genes downstream of Pdx1 and Ngn3

For a more in-depth analysis of the impact of Pdx1 and Ngn3 expression on lineage development, we carried out a microarray analysis to identify genes activated downstream of Pdx1 and Ngn3.
For these studies, gene expression in Dox-stimulated tet-pdx1/ngn3 Ainv cells cultured under Protocol #2, with BMP4 and floating non-adherent conditions for 13 days, were evaluated by microarray analysis and compared to gene expression of E15.5 embryonic pancreas, adult islet cells, and βTC6 cells. All primary microarray data are available at http://www.ncbi.nlm.nih.gov/geo/ under accession numbers GSM586113-122 and GSM312098-127.

With this analysis we found that other pancreas-related genes are upregulated by Pdx1 and Ngn3 (supplemental Table S3). These genes were categorized based on gene ontology analysis as follows: 1) “Extracellular” secretory proteins including: A) pancreatic endocrine and exocrine genes (Ins1, Sst, Gcg, Ppy, Ghrl and Cpa); B) genes related to insulin secretion (Sg, Chga, Pcsk); and C) enteroeendocrine genes (Gip, Gck, Ppy and Ghrl); 2) “Nuclear” transcription factors, including β-islet cell-related transcription factors (Pax6, Islm1, Neurod1, Nkx2.2, Isl1, Hhex, Nkx6.1 and Pax4) and α-cell-related transcription factors (Arx, Ins2); and 3) “Miscellaneous”, which includes genes whose direct functional role in β-islet differentiation is not clear, i.e. cytoskeletal/membrane and cytoplasmic/signaling genes. The upregulation of some of the Miscellaneous genes, e.g. (Dox, Sima2 and Tubb3), is consistent with an earlier study evaluating novel Ngn3-related genes in mouse ES cells [29]. To determine the time course of the expression of these genes under Protocol #2 culture conditions, microarray analyses were performed on days 4, 6 and 13. Selected pancreas-related genes (Ins1, Gip, neurod1, Sst, Seg3, Islm1, Gcg, Pax6, and Arx) indicate that there is a significant upregulation of these genes after day 6, suggesting differentiation from endoderm to a pancreatic fate during this time period (Supplemental Fig. S1).

Depletion of N2 and RA increases Ins1 mRNA levels

Protocol #2 used in this study was originally established for hepatocyte differentiation from mouse ES cells [22]. To optimize β-islet cell differentiation we tested whether N2 or RA, supplements that we used for differentiating hepatocytes, were useful for pancreatic EB differentiation and Ins1 expression. We explored this with Protocol #3, which is identical to Protocol #2 except that N2 and B27 (−RA, i.e.-without RA), were not used at any time during the culture, and after day 6 the cells were grown in suspension (see Supplemental Table S1). We found that the highest Ins1 expression was obtained when both N2 and RA were removed from the protocol, which resulted in an increased Ins1 mRNA level to 23% of that in βTC6 cells (Fig. 4A). FACS analyses indicated that approximately 27% of Dox-stimulated EBs cultured under Protocol #3 for 18 days showed cytoplasmic insulin staining (Fig. 4B). This insulin expression was dependent on the expression

Figure 3. Time course of pancreas-related gene expression. Tet-pdx1/ngn3 ES cells were cultured according to Protocol #2, with BMP4. Pdx1 and Ngn3 were induced with Dox (Dox+) or without (Dox−) at day 4, and gene expression was analyzed from day 9–16 by RT-PCR and compared to βTC6 mRNA. (A) Secretory proteins and liver/intestine related-genes. (B) Insulin processing genes and glucose sensing genes. (C) Pancreas related-transcriptional factors.
doi:10.1371/journal.pone.0024058.g003
of Pdx1 and Ngn3 since only 1% of EBs cultured in the absence of Dox were positive for insulin (Fig. 4B).

C-peptide is secreted from EBs induced by Pdx-1 and Ngn3

To evaluate pancreatic hormone secretion, pancreatic EBs were cultured for 18 days under Protocol #3, after which the medium was replaced with fresh medium for 24 hours and supernatants were harvested. C-peptide, glucagon and somatostatin were measured by either RIA (C-peptide) or EIA (glucagon, somatostatin) as described in Materials & Methods. (C) EBs were cultured according to Protocol #3 for 18 days with or without Dox, after which the supernatant was harvested and C-peptide was measured by RIA. For the Dox samples in panels C & D, C-peptide and somatostatin values were not detectable above background. The data presented are mean of three independent experiments; the error bars represent the SEM. *p<0.05 as compared with Dox (−), **p<0.05 as compared with Dox (+).

doi:10.1371/journal.pone.0024058.g004

Figure 4. Deletion of N2 and RA supplements increases Ins1 expression. Tet-pdx1/ngn3 ES cells were cultured with Dox (Dox+) or without (Dox−) according to Protocol #3, including B27 supplement formulated with or without RA as indicated. (A) N2 supplement was added to the indicated groups from the beginning through day 14. B27(+RA), indicated by “+”, or B27(−RA), indicated by “−”, was included as a supplement from either day 0–4 or from day 4–14 as indicated. Ins1 mRNA levels at day 14 were quantified by real time PCR and normalized to βTC6 levels. (B) Tet-pdx1/ngn3 ES cells were cultured with Dox (Dox+) or without (Dox−) according to Protocol #3 for 18 days. EBs were trypsinized to make single cell suspensions and cytoplasmic insulin was detected by immunostaining and analyzed by FACS. (C) EBs were cultured according to Protocol #3 for 18 days with or without Dox, after which the media was replaced with fresh medium for 24 hours and supernatants were harvested. C-peptide, glucagon and somatostatin were measured by either RIA (C-peptide) or EIA (glucagon, somatostatin) as described in Materials & Methods. (D) EBs cultured according to Protocol #3 for 19 days were resuspended in HKRB buffer and stimulated with KCl (30 mM), Forskolin (10 μM) or IBMX (0.5 mM) for 1 hour. Supernatants were harvested and C-peptide was measured by RIA. For the Dox− samples in panels C & D, C-peptide and somatostatin values were not detectable above background. The data presented are mean of three independent experiments; the error bars represent the SEM. *p<0.05 as compared with Dox (−), **p<0.05 as compared with Dox (+).

doi:10.1371/journal.pone.0024058.g004

Immunohistochemical analysis of pancreas-related proteins

We next carried out an immunohistochemical analysis to evaluate protein expression in EBs in which Pdx1 and Ngn3 were
induced. Tet-pdx1/ngn3 ES cells were cultured for 16 days under Protocol #3, with or without Dox, and then replated on glass bottom dishes coated with Matrigel. On day 16, the EBs were immunostained and examined using confocal microscopy. We found that insulin, C-peptide, Chga and Pcsk2 proteins are all expressed in Dox-stimulated EBs (Fig. 5), whereas no staining is detected in EBs not stimulated with Dox (data not shown). Importantly, most insulin-positive cells co-expressed C-peptide. As positive controls, we also stained for Pdx1 and Ngn3 after Dox stimulation (Fig. 5). Our results suggest that the temporal upregulation of Pdx1 and Ngn3 induces endocrine pancreas cells that produce β-cell-related proteins. The fact that detecting insulin protein and C-peptide was dependent on Dox-regulation indicates that these results are detecting endogenously produced insulin and are not subject to previous published insulin artifacts [30].

Removal of B27 from DMEM enhances pancreatic differentiation

After culturing tet-pdx1/ngn3 ES cells under Protocol #3 for 6 days, we cultured the cells for the next 12 days according to Protocol #3 or a modified Protocol #3 in which the IMDM/F12 was replaced with DMEM (Protocol #4). We found that levels of Ins1 mRNA were higher in the group that contained DMEM instead of IMDM (Fig. 6A). Moreover, using different concentrations of B27(-RA) according to Protocol #4 revealed that eliminating B27(-RA) after day 6 resulted in an increased Ins1 expression that reached 66% of βTC6 levels on day 18 (Fig. 6B). Ins1 mRNA ultimately reached 100% of the level in βTC6 cells by day 26 (Fig. 6C). Immunostaining showed that there was a higher fraction of cells positive for both insulin and C-peptide when cells were cultured according to Protocol #4, without B27(-RA) after day 6, compared to Protocol #3 (compare Fig. 6D with Fig. 5). Using FACS analyses, we also confirmed that 43% of cells from Dox-stimulated EBs cultured under Protocol #4, without B27, showed cytoplasmic insulin (Fig. 6E), whereas only 1.0% of EBs cultured in the absence of Dox were insulin-positive (data not shown). Under these conditions the 24 hour secretion of C-peptide increased approximately 4-fold and 10-fold on days 18 and 26, respectively, as compared to Protocol #3 (compare Fig. 6F with Fig. 4C). Although these conditions resulted in very high Ins transcription levels and frequency of insulin positive cells, this increased level of C-peptide secretion was still less than 1% of the level of C-peptide secreted from βTC6 cells, which was 3766 ± 92 ng/mg protein/24 hour (data not shown). Under these conditions, tolbutamide significantly increased C-peptide secretion measured at one hour of stimulation, whereas high glucose did not (Fig. 6G).

Discussion

Efficient endodermal differentiation is a critical first step in pancreatic development, since the pancreas is an endoderm-derived tissue. We previously established two types of differentiation protocols for generating definitive endoderm from ES cells [21,22]. We show here the utility of temporally upregulating the expression of Pdx1 and Ngn3, which are known to be important for pancreatic development, can induce at high frequency the differentiation of endodermal cells into β-islet cells that transcribe insulin at high levels, and that these cells secrete C-peptide, respond to insulin secretagogues, but do not respond to glucose.

When Pdx1 is upregulated after the induction of endodermal differentiation, the transcription of both Ins1 and Ins2 increased, and when both and Pdx1 and Ngn3 were co-expressed, Ins1 and Ins2 transcription was upregulated to a significantly greater extent, reaching maximal levels in half the time. These results are consistent with a large body of evidence of the importance of Pdx1 and Ngn3 expression for the normal development of β-islet cell function and insulin expression. Pdx1 is first expressed in the pancreatic bud of the gut tube [10,12]. All pancreatic cell types are derived from Pdx1-positive progenitors [16], and Pdx1 is required for Ins transcription [10,31,32]. Previous reports have shown that Ngn3 is expressed in the embryonic pancreas at E10.5, and mice lacking Ngn3 fail to generate pancreatic endocrine cells [15]. In addition, cell tracking experiments showed that all β-islet cells are derived from precursors that express Pdx1 before they express Ngn3 [16,33], and that the four types of islet endocrine cells are derived from Ngn3-positive precursors [16]. These results suggest that Pdx1 is involved in the induction of endoderm to a pancreatic fate, after which Ngn3 induces the specification and differentiation of pancreatic endocrine cells from pancreatic primordium, and Pdx1 continues to be required for insulin expression and normal β-islet cell function. Moreover, expression of Pdx1 and Ngn3 was recently reported to be key events in β-islet cell regeneration from pancreatic duct cells in vivo [34]. These results, together with the...
Figure 6. DMEM media improves pancreatic differentiation of mouse ES cells. Tet-pdx1/ngn3 ES cells were cultured under Protocol #3 for 6 days, with Dox-induction of Pdx1 and Ngn3 expression starting at day 4. A) From day 6 through day 18 EBs were cultured according to Protocol #3 ("IMDM/F12") or in medium in which the IMDM/F12 was replaced with DMEM ("DMEM") as indicated (Protocol #4), and Ins1 mRNA was quantitated at day 18. B) EBs were cultured according to Protocol #4 for the first 6 days and with Dox-induction of Pdx1 and Ngn3 expression starting at day 4. From day 6 through day 18 various concentrations of B27(-RA) were added as indicated. Ins1 mRNA was quantitated at day 18. C) EBs were cultured according to Protocol #4 for 6 days, with Dox-induction of Pdx1 and Ngn3 expression starting at day 4. From day 6 through day 26 the medium was only DMEM with BSA without B27(-RA). Ins1 mRNA was quantitated from day 13–26. (D–G) Tet-pdx1/ngn3 ES cells were cultured according to Protocol #4 for 24 days with Dox induction starting at day 4. D) EBs were replated at day 24 and cultured in DMEM (BSA). At day 26, Insulin was visualized with a Cy3-conjugated 2nd antibody (red) and C-peptide was visualized with a FITC-conjugated 2nd antibody (green). Nuclei were stained with DAPI (blue). Magnification was with a 400x objective. E) EBs, prepared as in panel D, were trypsinized to make single cell suspensions and cytoplasmic insulin was stained and analyzed by FACS. F) EBs were cultured under Protocol #4 for 6 days, with Dox-induction of Pdx1 and Ngn3 expression starting at day 4. From day 6 through day 18 only one group was supplemented with B27(-RA) (1%) as indicated. On either day 18 or day 26 the media was replaced with fresh DMEM with BSA. Supernatants were harvested after 24 hours, and C-peptide was measured by RIA. The data
results presented here, suggest that the same machinery may be important for fetal islet development, adult islet regeneration, and ES cell-derived pancreatic differentiation.

To optimize the conditions that promote ES-derived pancreatic differentiation, we evaluated Protocol #2. Gouon-Evans et al. originally developed this protocol (“SFD”) for mouse ES-derived hepatocyte differentiation and showed that BMP4 is required for hepatic differentiation under this protocol [22]. It is important to note that all of the protocols we have studied require activin to initiate high efficiency generation of endoderm. Here we demonstrate that exogenous BMP4 improves mouse ES-derived pancreatic differentiation and increases Ins1 mRNA levels. BMP4 also reportedly promotes the proliferation and development of epithelial islet-like structures and pancreatic progenitor cells in vitro [35,36]. The recent work of Wandzioch and Zaret also actually shows that in the mouse embryo, BMP is required at a later time point for pancreas specification compared to liver specification [28]. In the present study, we found that changes to Protocol #2 culture medium, namely adding BMP4, using DMEM instead of IMDM/F12, eliminating the N2 and B27 supplements, culturing the cells in 3D non-adherent structures, i.e. Protocol #4, dramatically increased Ins1 mRNA levels up to 100% of the normalized values seen in βTC6 insulinoma cell line. Under these conditions, although the EB size was smaller than observed with Protocol #2, the relative number of insulin positive cells increased. This suggests that Protocol #4 provides a relative enrichment for insulin-positive cells. EBs induced toward pancreatic differentiation by the above protocols express a variety of pancreas-related proteins detected immunohistochemically, including Chga, Pdx2, plus fully processed insulin and C-peptide. In addition, insulin was processed and C-peptide was secreted into the supernatant. This suggests that Pdx1 and Ngn3 induce efficient differentiation of functional islet-like cells from ES cell-derived endoderm and that the cells are capable of producing and correctly processing insulin.

This in vitro differentiation process mimics embryonic pancreatic endocrine development, which can be useful for evaluating the gene expression pattern of pancreatic endocrine cell differentiation and β-islet cell biology. To evaluate this, we performed microarray analyses of Pdx1- and Ngn3-induced EB differentiation. Through these analyses we found that pancreas-related genes encoding secretory proteins (e.g., Ins and Sfd) and transcription factors (e.g., Pax6 and neuroD) were induced by Pdx1 and Ngn3 during EB differentiation. Conversely, genes characteristic of hepatocyte and intestine were suppressed by Pdx1 and Ngn3. This accurately reflects the known functional tissue specificity of these genes. In addition, other genes recently reported to play a role in pancreas development were also shown to be upregulated in Pdx1- and Ngn3-induced EBs. For example, cocaine- and amphetamine-regulated transcript (Cart) is upregulated in our studies and was recently reported to be expressed in pancreatic β-islet cells and to enhance insulin secretion from an insulinoma cell line and from isolated rat islet cells [37,38]. Resp18 is increased 87-fold by Pdx1/Ngn3 induction in our studies and was also recently reported to be expressed in pancreatic β-islet cells and markedly stimulated following exposure to high glucose [39]. Another study showed that genes expressed in endocrine cells (e.g., Gip, Cik, Py and Ghl) were upregulated, suggesting that these genes important for both endocrine and pancreatic hormones are dependent on the expression Pdx1 and/or Ngn3.

Consistent with normal β-islet cell biology, direct depolarization of the ES-derived cells using KCl or IBMX- or forskolin-induced intracellular cAMP increase, stimulated C-peptide release from the ES-derived pancreatic cells during a 1-hour secretion assay. These combined results indicate that ES-derived pancreatic cells produce and correctly process insulin and that C-peptide secretion is regulated by various insulin secretagogues. Despite the fact that Ins1 mRNA levels were comparable to those found in βTC6 cells in protocol #4 differentiated cells, C-peptide secretion was not glucose responsive and was only 0.75% of the normalized levels observed in βTC6 cells. Apparently, the current protocol does not induce at high efficiency the final maturation steps that result in adult-level glucose responsiveness. By using various growth factors at each differentiation step, D’Amour et al. were able to differentiate insulin-expressing cells from human ES cells [24] that could respond to glucose in vivo and could be used to successfully treat diabetic mice, suggesting that they were functionally glucose responsive [40]. It is not clear from D’Amour’s studies if the β-islet cells were glucose responsive in vitro prior to transplantation in vivo. It is possible that in vivo conditions are required for the final maturation steps leading to fully mature functional properties, which are not yet replicated in our culture systems. The identification of the potential biological factors and/or cellular interactions that are required for final β-islet cell maturation and full glucose responsiveness remains an elusive problem and as yet not replicated in vitro.

In conclusion, we have shown that mouse ES cells can be induced by activin to differentiate into definitive endoderm, followed by differentiation to pancreatic endocrine cells through subsequent stimulation of BMP4 and overexpression of Pdx1 and Ngn3. During this differentiation scheme, many gene expression cascades that mimic embryonic pancreatic development are expressed in an appropriate temporal order, suggesting this in vitro model may be useful as a screen for evaluating potential genes, or drug candidates, that induce or increase pancreatic endocrine cell differentiation. In addition, it is clear that further work is necessary to define the requirement for efficient and reproducible induction of full β-islet cell maturation and glucose responsiveness in vitro. These studies also highlight some of the limitations of current differentiation protocols as well as offer improved protocols that dramatically improve the frequency and level of insulin expression. These studies further support the view that ES cells, and iPSC by extension, have the potential to be a renewable resource for producing β-islet cells for cell-based diabetes therapy.

**Methods**

**Growth and Differentiation of ES cells**

We used Ainv 18 mouse ES cells (a kind gift from Drs. Michael Kyba and George Daley; ATCC SCRC-1029) to assess gene function during ES cell differentiation to pancreatic lineages [41]. These cells were engineered to allow “cre-lox” targeted insertion of “tet-on” expression cassettes into the hprt locus. This system enables the efficient temporal upregulation of target genes by the addition of Dox (Sigma, St. Louis). For some experiments, the bicistronic expression of two target genes was achieved through the
use of an intervening IRES sequence [42]. Pdx1 or pdx1-IRES-ngn3 pLOX expression vectors were electroporated, together with a cre expression construct [43], into Ainv 18 ES cells according to previously described [21]. To generate EBs, ES cells were propagated two times on gelatin, dissociated into a suspension of single cells using trypsin (0.25%), and then cultured at various concentrations in 60 mm bacterial-grade petri dishes (Valmark) in differentiation media, as described below. Cultures were maintained in a humidified chamber under a 5% CO2-air mixture at 37°C.

Four protocols were evaluated for differentiation of pancreas-like cells (see details in Supplemental Table S1). The first protocol utilized activin-mediated induction of endoderm via a two-step endoderm Protocol #1 (“SP protocol”) as previously described [21]. Dissociated undifferentiated ES cells (4×10⁶ cells/ml) were cultured for 2 days in suspension in Stem Pro 34 medium (Gibco) supplemented with 2 mM glutamine, 0.5 mM ascorbic acid, 4.5×10⁻⁴ M monothioglycerol (MTG) and c-kit ligand (1% conditioned medium from CHO cells). EBs were harvested after 48 hours of differentiation, allowed to settle in a 50 ml tube, transferred to new petri dishes (Valmark) and cultured for 4 days in IMDM supplemented with 15% Knockout serum replacement (SR) (Gibco), 2 mM glutamine, 0.5 mM ascorbic acid, 4.5×10⁻⁴ M MTG and human activin A (100 ng/ml) (R&D Systems). To induce test genes, starting on day 6 after EB formation, Dox (1 μg/ml) was included in IMDM supplemented with 15% SR, 2 mM glutamine, 0.5 mM ascorbic acid, and 4.5×10⁻⁴ M MTG. After differentiation for 10 days from the start of differentiation, the EBs were transferred to Matrigel-coated 6-well dishes (Falcon) in IMDM supplemented with 15% fetal calf serum (FCS; JRH) and 2 mM glutamate, with or without Dox (1 μg/ml). Cells from these replicated cultures were harvested for RNA isolation at the indicated times from the start of initial differentiation.

Protocol #2 used serum-free differentiation medium, as previously described (“SFD protocol”) [22], that contains 75% IMDM and 25% Ham’s F12 medium (Gibco) supplemented with 0.5% N2 and 1% B27 (with vitamin A/retinoic acid, “RA”) (Gibco), 1% penicillin/streptomycin, 0.05% bovine serum albumin, 2 mM glutamine, 0.5 mM ascorbic acid and 4.5×10⁻⁴ M MTG. ES cells (2–4×10⁶ cells/ml) were cultured in this medium in 60 mm low attachment petri dishes. On day 2 of differentiation, EBs were dissociated with trypsin/EDTA and replated at a density of 2–6×10⁴ cells/ml in new 60 mm petri dishes using Protocol #2 medium supplemented with activin A (50 ng/ml). On day 4, EBs were dissociated with trypsin/EDTA and then reaggregated at high density (5×10⁵ cells/ml) in 24-well low-cluster dishes (Nunc) in Protocol #2 medium supplemented with BMP4 (50 ng/ml) (R&D Systems), bFGF (10 ng/ml) (R&D Systems) and activin A (50 ng/ml), with or without Dox (1 μg/ml). On day 6, EBs were replated on gelatin coated 6-well dishes (Falcon) for monolayer culture or in 12-well low-cluster dishes (Nunc) to obtain non-adherent floating EBs in Protocol #2 medium, with N2 and/or B27(+/-RA), without either ascorbic acid or MTG, and with or without Dox (1 μg/ml). Protocol #3 was identical to Protocol #2 except B27 did not contain RA, media was not supplemented with N2, and after day 6 the cells were cultured in low-cluster dishes to obtain non-adherent floating EBs. Protocol #4 was identical to Protocol #3 except DMEM was used instead of IMDM/F12 media.

**PCD Gene expression analysis**

For RT-PCR, total RNA was extracted using RNeasy mini-kits and treated with RNase-free DNase (Qiagen). One μg of total RNA was reverse-transcribed to cDNA using a Superscript RT kit (Invitrogen) with random hexamers. PCR was carried out using Taq polymerase (Takara Bio) in PCR buffer containing 2.5 mM MgCl₂ and 0.2 μM dNTPs. The amplification protocol was 1 cycle at 94°C for 5 min followed by 25–40 cycles of 94°C for 1 min (denaturation), 60°C for 30 sec (annealing) and 72°C for 1 min (elongation), with a final elongation at 72°C for 7 min. The oligonucleotide primers used for PCR are listed in supplemental Table S2.

For quantitative real-time PCR, commercially available assay mixes (Applied Biosystems) for Ins1 (Mm01259683_g1), Ins2 (Mm00731595_gH) and 185 (Hs99999901_s1) were used to quantify mRNA levels, and PCR was performed using a Prism 7700 Sequence Detector (Applied Biosystems). Ins1 and Ins2 mRNA levels were normalized to 18S mRNA levels in the same samples, expressed as Ins1/18S ratios, and plotted as percentages of the Ins1/18S ratios observed in Btics cells grown in 15%FCS DME and harvested in log phase. All experiments repeated at least two times.

**Transient gene upregulation mediated by vector electroporation**
Pdx1, Nkx6.1 and Ngf3 coding regions were cloned downstream of the CMV promoter in the pIRE-EGFP vector (Clontech). Tet-pdx1 or tet-pdx1/ngn3 ES cells were cultured under Protocol #1. On day 6, EBs were dissociated with trypsin/EDTA (0.25%), after which the resultant cells (1–3×10⁶ cells) were suspended in mouse ES cell nucleiocfection solution (Amaza). Gene expression plasmids (5 μg) were electroporated into cells using an Amaza Nucleoector device (ES solution, program O-17). The cells were then washed and reaggregated in 24-well low-cluster dishes (Costar) in IMDM supplemented with 15% SR (Gibco), 2 mM glutamine, 0.5 mM ascorbic acid and 4.5×10⁻⁴ M MTG containing Dox (1 μg/ml). EBs were harvested on day 8 for FACS or on day 9 for RNA isolation.

**Microarray analysis**

For microarray analysis, total RNA was extracted using RNeasy mini kits (Qiagen), after which 10-μg samples of fragmented target total RNA was used for hybridization of CodeLink Mouse Whole Genome Arrays (GE Life Sciences), which contained 34,967 probes. Once the microarrays were hybridized and washed, biotin-containing transcripts were directly detected using a Streptavidin-Alexa647 conjugate as previously described [44]. GeneSpring 7 (Silicon Genetics, Inc., Redwood City, CA) was then used to evaluate the data obtained using CodeLink™ Expression Scanning Software. Because some CodeLink probes are improperly annotated as to their intended target, refinement of gene-to-probe associations was accomplished by analysis using VistaGen’s Valid Probe Set tools, which results from a mapping of the genomic coordinates of probes with that of the exons of genes. All genomic coordinates of the mouse genome were determined using BLAST. Unvalidated probes, such as those that target multiple genes, non-coding strand, or intergenic regions on the genome, were removed from analyses.

**FACS analysis and cell sorting**

We used our previously published methods to isolate definitive endoderm populations [22,45]. Day 4 EBs were trypsinized for single cell suspension, then stained with a PE-conjugated anti-c-kit...
antibody (BD Pharmingen, 553355, 1/150) and a biotinylated rat anti-mouse CXCR1 antibody (BD Pharmingen, 551968, 1/200), and visualized using streptavidin PE-Cy5 (BD Pharmingen). Cytoplasmic insulin was detected in cells from day 10 EBs dissociated with 0.25% trypsin/EDTA and 0.05% collagenase, stained with a guinea pig anti-insulin antibody (Dako, A0564 1/100), and visualized using a PE-conjugated anti-guinea pig IgG secondary antibody (Jackson Immunoresearch) with the Cytofix/ Cytoperm kit (Becton Dickinson) according to manufacturer’s recommendations. The stained cells were also analyzed using a FACScan (Becton Dickinson, San Jose, CA) or sorted on a FACS Aria cell sorter (Becton Dickinson). All experiments repeated at least two times.

Immunostaining

For immunostaining, day 16 EBs were plated on glass bottom dishes (MatTek) coated with Matrigel. Two days later, the day 18 EBs were fixed in 4% paraformaldehyde for 20 min, washed two times in PBS, permeabilized in PBS containing 0.2% Triton-x100, washed in PBS containing 10% FCS and 0.2% Tween 20, and then blocked for 10 min in PBS containing 10% horse serum. The cells were then incubated for 1 hour with a primary antibody specific for either insulin (Dako, A0564, 1/150), C-peptide (Yanaihara, Y222, 1/100), Pdx1 (Transgenic, KR059, 1/100), Ngn3 (Santa Cruz sc-25655, 1/50), Pck2 (Chemicon, AB1262, 1/100) or Chga (Epitomics, #1782-1, 1/100), and visualized using a Cy3-conjugated anti-guinea pig IgG secondary antibody or FITC-conjugated anti-rabbit IgG secondary antibody (Jackson Immunoresearch, 1/200) as appropriate. After the second staining step, the EBs were washed and covered with anti-fluor reagent containing DAPI (Molecular Probe). Images were then captured using a FLUOVIEW FV1000 confocal microscope (Olympus) with 10×, 40× and 100× objectives. All experiments repeated at least two times.

Measurement of C-peptide, glucagon and somatostatin secretion from EBs

After culturing EBs for 17–18 days in Protocol #3 medium, with or without Dox (1 μg/ml), the medium was changed to fresh IMDM/F12/BSA/B27(−RA) media, with 2 mM glutamine and no growth factors. The EBs were then incubated for 24 hours as indicated, after which the conditioned medium was collected for secretion assays. Concentrations of glucagon and somatostatin in the conditioned medium were measured using enzyme immunoassays (EIAs) specific for glucagon (Yanaihara) or somatostatin (Phoenix Pharmaceuticals) according to the manufacturer’s instructions. To assay C-peptide secretion, day 18 EBs were washed and then incubated for 1 hour in Krebs-Ringer bicarbonate HEPES buffer (2 mM glucose) with or without stimulation with secretagogues. C-peptide in the supernatant was then measured using a specific radioimmunoassay (RIA; Linco). The amount of protein in each sample was determined using BCA assays (Pierce), and measured levels of secreted C-peptide, glucagon and somatostatin were normalized to the total protein.

Supporting Information

Figure S1 Time course of pancreatic gene expression.

Tet-pdx1/ngn3 ES cells were cultured according to Protocol #2 with BMP4 and cultured in suspension. Pdx1 and Ngn3 were induced with or without Dox starting at day 4, and cells were harvested at the indicated time points. Various pancreatic related-genes were analyzed by microarrays. Dox(−); open squares, Dox(+); closed circles. (TIF)

Table S1 Protocol for culture conditions.

Table S2 Oligonucleotide primers used for PCR.

Table S3 Microarray gene expression analysis.

Tet-pdx1/ngn3 ES cells were cultured according to Protocol #2 with BMP4 and cultured in suspension. Pdx1 and Ngn3 were induced with or without Dox starting at day 4, and cells were harvested at the indicated time points. RNA samples were isolated from day 13 EBs with or without Dox, βTC6 cells and e15.5 mouse embryo and various pancreatic related-genes were analyzed by microarrays.

Acknowledgments

We thank Drs. Michael Kyba and George Daley (Whitehead Institute, USA) for a kind gift of A7v18 ES cells and plox system. We also thank Ms. Mako Yabunouchi and Ms. Fumie Otsuka for their excellent technical assistance.

Author Contributions

Conceived and designed the experiments: AK GK RS. Performed the experiments: AK RS MT KB MS. Analyzed the data: AK RS MT KB. Contributed reagents/materials/analysis tools: VG-E MI YS. Wrote the paper: AK GK RS.

References

1. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, et al. (2000) Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343: 230–238.

2. Shapiro AM, Racord C, Hering BJ, Aucinhiusz H, Lindblad R, et al. (2006) International trial of the Edmonton protocol for islet transplantation. N Engl J Med 355: 1318–1330.

3. Bonner-Weir S, Tanjea M, Weir GC, Tatarkiewicz K, Song KH, et al. (2000) In vitro cultivation of human islets from expanded ductal tissue. Proc Natl Acad Sci U S A 97: 7999–8004.

4. Seaberg RM, Smukler SR, Kieffer TJ, Enikolopov G, Azhar Z, et al. (2004) Epithelial-to-mesenchymal transition generates proliferative human islet progenitor cells. Science 306: 2261–2264.

5. Smith AG (2001) Embryo-derived stem cells: of mice and men. Annu Rev Cell Dev Biol 17: 433–462.

6. Kellner GM (1999) In vitro differentiation of embryonic stem cells. Curr Opin Cell Biol 7: 862–869.

7. Habener JF, Kemp DM, Thomas MK (2005) Minireview: transcriptional regulation in pancreatic development. Endocrinology 146: 1025–1034.

8. Murtaugh LC, Melton DA (2003) Genes, signals, and lineages in pancreas development. Annu Rev Cell Dev Biol 19: 71–89.

9. Ohlsson H, Karlsson K, Edlund T (1993) IPF1, a homeodomain-containing transactivator of the insulin gene. Endo J 12: 4251–4259.

10. Leonard J, Peers B, Johnson T, Ferrers K, Lee S, et al. (1993) Characterization of somatostatin transcribing factor-1, a novel homeobox factor that stimulates somatostatin expression in pancreatic islet cells. Mol Endocrinol 7: 1275–1283.

11. Miller CP, McGehee RE, Jr., Habener JF (1994) IDN-1: a new homeodomain transcription factor expressed in rat pancreatic islets and duodenum that transactivates the somatostatin gene. Endo J 13: 1145–1156.

12. Jonsson J, Carlsson L, Edlund T, Edlund H (1994) Insulin-promoter-factor-1 is required for pancreas development in mice. Nature 371: 606–609.

13. Gupta-Botton A, Majithia AR, Melton DA (2001) Key events of pancreatic formation are triggered in gut endoderm by ectopic expression of pancreatic regulatory genes. Dev Genes 15: 444–454.

14. Gajewski T, Dierich A, LeMeur M, Guillomet F (2000) Neurogenin3 is required for the development of the four endocrine cell lineages of the pancreas. Proc Natl Acad Sci U S A 97: 1607–1611.

15. Gu G, Dubashkaite J, Melton DA (2002) Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development 129: 2447–2457.
17. Sosa-Pineda B, Chowdhury K, Torres M, Oliver G, Gruss P (1997) The Pdx4 gene is essential for differentiation of insulin-producing beta cells in the mammalian pancreas. Nature 386: 399–402.

18. Naya EF, Chuang HP, Qu Y, Mutoh H, DeMayo FJ, et al. (1997) Diabetes, defective pancreatic morphogenesis, and abnormal endocrine differentiation in BETAV2/neuroD-deficient mice. Genes Dev 11: 2323–2334.

19. Sussel L, Kalamaras J, Hartigan-O’Connor DJ, Meneses JJ, Pedersen RA, et al. (1998) Mice lacking the homeodomain transcription factor Nkx2.2 have diabetes due to arrested differentiation of pancreatic beta cells. Development 125: 2213–2221.

20. Sander M, Sussel L, Conners J, Scheel D, Kalamaras J, et al. (2000) Homeobox gene Nkx6.1 lies downstream of Nkx2.2 in the major pathway of beta-cell development in the pancreas. Development 127: 5533–5540.

21. Kubo A, Shimozaki K, Shannon JM, Kouskoff V, Kennedy M, et al. (2004) Development of definitive endoderm from embryonic stem cells in culture. Development 131: 1651–1662.

22. Gouon-Evans V, Boussouani L, Gasche P, Niehoff D, Koehler CI, et al. (2006) BMP-4 is required for hepatic specification of mouse embryonic stem cell-derived definitive endoderm. Nat Biotechnol 24: 1402–1411.

23. D’Amour KA, Agulnick AD, Eliazer S, Kelly OG, Kroon E, et al. (2005) Efficient differentiation of human embryonic stem cells to definitive endoderm. Nat Biotechnol 23: 1534–1541.

24. D’Amour KA, Bang AG, Eliazer S, Kelly OG, Agulnick AD, et al. (2006) Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol 24: 1392–1401.

25. Bernardo AS, Cho CH, Mason S, Docherty HM, Pedersen RA, et al. (2009) Biphasic induction of Pdx1 in mouse and human embryonic stem cells can mimic development of pancreatic beta-cells. Stem Cells 27: 341–351.

26. Delour L, Leduque P, Blume N, Madsen O, Dubois P, et al. (1993) Differential expression of the two nonallelic proinsulin genes in the developing mouse embryo. Proc Natl Acad Sci U S A 90: 527–531.

27. Jiang FX, Stanley EG, Gonce LJ, Harrison LC (1997) The Pax4 gene is essential for differentiation of insulin-producing beta cells in the mammalian pancreas. Nature 386: 399–402.